Effect of ovarian steroids on vascular endothelial growth factor a expression in bovine uterine endothelial cells during adenomyosis

Table 1 Relative abundance of VEGFA, VEGFR1 and VEGFR2 in: non-adenomyotic uterine tissue (control), tissue at the stages 1–2 of adenomyosis (1^o-2^o) and tissue at the stages 3–4 of adenomyosis (3^o -4^o). Abundance level was determined by IHC staining intensities indicated as follows: + weak staining, ++ moderate staining, +++ strong staining, N/A not applicable

	VEGFA			VEGFR1			VEGFR2
	control	1^o-2^o	3^o-4^o	control	1^o-2^o	3^o-4^o	control	1^o-2^o	3^o-4^o
endometrial glands	+++	+++	+++	++	++	++	+	+	+
endometrial blood vessels	++	++	++	++	++	++	++	++	++
endometrial stroma	+	+	+	+	+	+	+	+	+
myometrium	++	++	++	++	+	++	+	+	+
glands within adenomyotic lesions	N/A	+++	+++	N/A	++	++	N/A	+	++
myometrial blood vessels	++	++	++	++	+	+	++	++	++

VEGFA vascular endotelial growth factor A, VEGFR1 vascular endotelial growth factor receptor 1, VEGFR2 vascular endotelial growth factor receptor 2, control tissue without adenomyosis, 1^o-2^o adenomyosis stages 1–2, 3^o-4^o adenomyosis stages 3–4

ISSN: 1746-6148